Eli Lilly Acquires Orna Therapeutics for $2.4 Billion to Advance Circular RNA Platform

Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total transaction value of up to $2.4 billion. The deal centers on Orna's proprietary circular RNA (oRNA) technology and its pioneering "in vivo" CAR-T platform, which promises to revolutionize how cellular therapies are delivered to patients.

By integrating Orna's pipeline, Lilly is signaling a strategic pivot toward "off-the-shelf" genetic medicines that can reprogram a patient's immune system directly inside the body, bypassing the costly and logistically complex manufacturing processes of traditional cell therapies. This acquisition marks one of the largest bets to date on circular RNA—a more stable and durable alternative to the linear mRNA used in current vaccines. As of February 25, 2026, the market is already reacting to the news, with Lilly's stock showing resilience despite broader sector volatility.

The acquisition follows a string of breakthrough clinical milestones that culminated in late 2025. During the 67th American Society of Hematology (ASH) Annual Meeting in December 2025, Orna presented landmark preclinical data for its lead candidate, ORN-252. A CD19-targeting "in vivo" CAR-T therapy, ORN-252 demonstrated the ability to achieve complete B-cell depletion in non-human primates at remarkably low doses. Most importantly, the therapy achieved these results without the need for lymphodepletion—the harsh "preconditioning" chemotherapy that has historically limited CAR-T usage to the most severe cases of cancer and autoimmune disease.

The timeline leading to the February 2026 announcement suggests that Lilly moved quickly following these results to preempt other bidders. Under the terms of the agreement, Lilly will pay an undisclosed upfront cash sum, with the remainder of the $2.4 billion tied to the achievement of specific clinical and regulatory milestones. Orna will be absorbed into Lilly's immunology research and early clinical development units, though it will maintain its research hub in Cambridge, Massachusetts, to continue refining its circular RNA delivery systems.

Key stakeholders, including Orna's early venture backers and its previous partners, have watched the deal closely. While Merck & Co. (NYSE: MRK) had established a $3.5 billion collaboration with Orna back in 2022, Lilly's full acquisition of the company means it now inherits the "engine" behind those programs. Initial market reactions have been overwhelmingly positive for Lilly; analysts at major firms have noted that Lilly is effectively utilizing the massive cash reserves generated by its blockbuster metabolic drugs, such as Mounjaro and Zepbound, to diversify into high-growth genetic medicine.

The primary winner in this transaction is undoubtedly Eli Lilly, which has successfully leapfrogged several years of internal R&D to become a frontrunner in the "in vivo" CAR-T race. By owning the oRNA platform, Lilly can now apply this technology across its vast portfolio of autoimmune and oncology indications. However, the deal creates a complex "competitor dilemma" for Merck & Co. (NYSE: MRK) and Vertex Pharmaceuticals (NASDAQ: VRTX). Both companies have existing partnerships with Orna; while Lilly is expected to honor these contracts, it now sits in the driver's seat of the technology they rely on, potentially complicating future intellectual property sharing and resource allocation.

In the broader CAR-T space, established players like Gilead Sciences (NASDAQ: GILD) and Bristol Myers Squibb (NYSE: BMY) face increased pressure. These companies have invested billions in "ex vivo" CAR-T facilities—massive factories where patient cells are shipped, modified, and shipped back. If Lilly's "in vivo" approach, which uses a simple injection of lipid nanoparticles (LNPs), proves successful in human trials, the multi-billion-dollar infrastructure of traditional CAR-T could become obsolete overnight. Consequently, Gilead and Bristol Myers Squibb may be forced to pursue their own "in vivo" acquisitions to remain competitive.

On the losing side, traditional biologics used for autoimmune diseases, such as those marketed by AbbVie (NYSE: ABBV), could see their long-term market share threatened. If ORN-252 can truly "reset" the immune system in lupus patients with a single treatment, the need for chronic, lifelong injections of monoclonal antibodies would drastically diminish.